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Introduction
The use of phosphate-based enemas as a laxative is still
standard practice in clinical medicine. Absorption of
phosphate with consecutive hyperphosphataemia and
hypocalcaemia is a serious adverse event which is
especially dangerous in patients with renal insuffi-
ciency and impaired bowel movement. Despite several
reports including cases of death, the seriousness of this
situation appears to be underestimated in clinical
practice [1,2].
We report a case of severe hyperphosphataemia
after kidney transplantation induced by phosphate-
containing enemas resulting in fatal calcifications.
Case report
A 64-year-old woman with end-stage renal failure due
to analgesic nephropathy had been on chronic
peritoneal dialysis for 18 months. Several years ago,
gastrectomy, oesophagojejunostomy and splenectomy
were performed because of a perforated gastric
ulcer. Secondary hyperparathyroidism was treated by
calcium-containing phosphate binders and calcitriol.
During the course of peritoneal dialysis, intact para-
thyroid hormone levels were decreased from 804 pg/ml
to 82 pg/ml. The calcium–phosphate molar product
was never higher than 56.5mg2/dl2 (4.5mmol2/l2).
Besides dialysis with disturbed calcium phosphate
balance, hypertension and a history of smoking existed
as cardiovascular risk factors. However, the patient’s
medical history was free from ischaemic vascular
events. Dobutamine stress echocardiography revealed
no cardiac ischaemia, and duplex sonography showed
no stenosis of the pelvic vessels. The patient received a
kidney graft from a marginal donor with a history of
hypertension and a prolonged warm ischaemia time.
The renal artery of the graft was arteriosclerotic. The
operative procedure was uneventful and no severe or
prolonged episode of hypotension occurred. However,
colouration of the graft from livid to rosy was
decelerated. The index biopsy revealed signs of
moderate arteriolar hyalinosis and interstitial fibrosis.
The induction immunosuppression consisted of basi-
liximab (20mg i.v. on days 0 and 4) combined with
methylprednisolone (1000, 500 and 250mg on days 0, 1
and 2–4, respectively), ciclosporin from day 4 on
(dosage adapted to serum drug levels from 250 to
350 mg/l), mycophenolate mofetil (1000mg orally twice
a day), and prednisone (125mg/day from day 5 with
tapering to 20mg). Due to primary non-function,
haemodialysis was started on day 1. Duplex ultrasound
showed a normal arterial flow and an accelerated flow
of the renal vein in the area of crossing the renal artery.
On the same day, a phosphate-based enema was
administered to stimulate bowel activity. During the
following night, severe hyperphosphataemia of
17.1mg/dl (5.55mmol/l) developed, with a concomi-
tant fall in serum calcium from 9.96mg/dl to 8.63mg/
dl (2.48–2.15mmol/l) and a calcium–phosphate molar
product of 147mg2/dl2 (12mmol2/l2). The episode of
hyperphosphataemia was accompanied by hypotension
(blood pressure 93/55mmHg) and liver enzymes
increased dramatically: aspartate aminotransferase
6666U/l, alanine aminotransferase 2096U/l and
lactate dehydrogenase of 6804U/l (Figure 1). Duplex
sonography of the kidney showed the same pattern
as the day before. Computed tomography of the
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abdomen revealed extensive lesions in the liver
compatible with ischaemic or drug-induced tissue
damage. Further, generalized atherosclerosis, including
the mesenteric vessels, was seen. Mycophenolate
mofetil was stopped, as a potential causative agent of
drug-induced liver failure. Immediately, an additional
haemodialysis was performed to remove phosphate.
After dialysis, phosphate levels decreased and
remained in a range from 3.46 to 8.48mg/dl (1.12–
2.74mmol/l). The liver enzymes returned to normal
levels within 7 days. Nevertheless, the patient’s
condition continued to deteriorate and she became
delirious. The abdomen remained distended without
any signs of bowel activity. During the weekend (on
day 6), unaware of the severe hyperphosphataemia on
day 2, two more phosphate-containing enemas were
instilled. Again, an increase of the serum phosphate
to 13.25mg/dl (4.28mmol/l) and a decrease in serum
calcium from 9.4mg/dl to 8.0mg/dl (2.34–1.99mmol/l)
with a calcium–phosphate molar product of 106mg2/dl2
(8.5mmol2/l2) was observed. The general condition
of the patient worsened and the kidney graft remained
non-functioning. On day 9, explorative surgery
revealed a dark blue kidney and a transplant nephrect-
omy was performed. Histologically, thrombosis of
the renal vein and a partial thrombosis of the artery
were found. The completely necrotic organ showed
massive nephrocalcinosis. After graft nephrectomy, the
patient’s condition improved only slightly. However,
on day 15 the patient suffered from feculent vomiting.
Laparotomy revealed a necrotic colon and pancreas.
Hemicolectomy, cholecystectomy and peripancreatic
necrosectomy were performed. Thirteen days later,
despite repeated second-look operations with debride-
ments and broad-spectrum antibiotics, the patient
developed septic shock and died of multiple organ
failure.
The histology of the colon, rectum and gall bladder
revealed severe calcifications of small and medium-
sized arteries and veins and regions of superficial and
transmural necrosis with calcifications. Intimal pro-
liferation, endovascular fibrosis and thrombosis of the
vessels were not found. In the liver, an infarct of 8 cm
with parenchymal calcifications and multiple haemo-
rrhagic infarcts (up to 4 4 8 cm) were present. The
peripheral and central veins within the infarcted areas
revealed subacute thromboses. The pancreas presented
a pattern of subacute pancreatitis and subacute,
partly organized thromboses of small peripancreatic
veins. In conclusion, severe dystrophic calcifications in
liver, colon, rectum, gall bladder and the kidney graft
in a patient with pre-existing generalized athero- and
arteriolosclerosis were diagnosed. Brain, lung and skin
showed no calcifications at all.
Discussion
Since the clinical trial of Vanner et al. [3] in 1990,
sodium phosphate preparations have been widely
prescribed as a safe and well-tolerated colonic cleans-
ing agent. They are, however, not recommended for
Fig. 1. Course of disease, x-axis: days after transplantation, y-axis: phosphate mg/dl (black triangle; asterisk: phosphate after first dialysis
session), calcium mg/dl (open triangle), aspartate aminotransferase U/l 1000 (open circle). NOTE: To convert serum phosphate in milligram
per decilitre to millimole per litre, multiply by 0.323; serum calcium in milligram per decilitre to millimole per litre, multiply by 0.250.
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patients with impaired renal function. In cases of
renal insufficiency, the development of severe, life-
threatening hyperphosphataemia with concomitant
hypocalcaemia has been described. This observation
is documented in several case series. Fass et al. [1]
summarized 28 cases. The patients were between
4 months and 81 years old. All of them received a
phosphate-based cathartic, most of them rectally. The
administered doses varied between 65 and 690ml
(mostly Fleet Phospo-Soda containing 15.4 g elemental
phosphate per 120ml). The observed increase in serum
phosphate varied between 4.3mg/dl (1.38mmol/l) and
67mg/dl (21.6mmol/l). Pre-disposing factors for
hyperphosphataemia in adults were chronic constipa-
tion, ileus, excessive enema use and renal insufficiency.
In five cases the outcome was poor, including brain
damage, cardiac arrest, coma and death in two
cases [1]. The reported mortality rate in cases of
severe hyperphosphataemia due to phosphate admin-
istration (rectally and orally) is about 33% (four of 12
patients) [4]. Recently, Markowitz et al. [5] reported 21
cases of acute renal failure following oral sodium
phosphate bowel cleansing. The most distinctive
finding in all cases was abundant calcium phosphate
deposits in distal tubules and collecting ducts. The
mean baseline creatinine was 1.0mg/dl [range 0.6–
1.7mg/dl (53–150 mmol/l)]. The renal outcome was
poor, all patients developed chronic renal insufficiency
with a mean serum creatinine of 2.4mg/dl [range
1.3–3.4mg/dL (115–300 mmol/l)] and four of them
required chronic haemodialysis.
Under normal conditions, up to 20% of the
phosphate in enemas is resorbed [6]. On day 1 after
transplantation, our patient received Practo-Clyss
120ml containing 2.9 g disodium hydrogenphosphate
(20.3mmol) and 14.8 g sodium dihydrogenphosphate
(122.8mmol). The volume of phosphate distribution is
not fixed and depends greatly on cellular and bone
uptake. Therefore, only a simple calculation is needed
to show that a moderate increase in phosphate absorp-
tion may be sufficient to cause severe hyperphos-
phataemia, especially if the renal excretion of
phosphate is disturbed. In our patient, assuming an
extracellular volume of 12 litre, only about 53mmol of
phosphate had to be absorbed to increase the serum
phosphate from 3.3mg/dl (1.06mmol/l) to 17.1mg/dl
(5.55mmol/l) as observed on day 1.
Hebert et al. [7] showed that the administered
phosphate lowers serum calcium by physiochemical
precipitation of CaHPO4 as its solubility product is
exceeded. In three of their patients, even calcium
deposits could be radiologically explored in the vein in
which phosphate was infused [7]. Otherwise, as shown
already in 1932 by Albright et al. [8], phosphate
administered to hypercalcaemic patients might result in
soft tissue calcification. Clinically, it is very important
at which site the CaHPO4 precipitation occurs.
As discussed by Floege et al. [9], the different
pathogenetic pathways of vascular, valvular, organ
and soft tissue calcifications in uraemic patients are
complex. Besides passive precipitation, due to an
excessive calcium phosphate product, active cellular
processes, systemic or local deficiency of inhibitory
factors to prevent precipitation and the local milieu
may be important factors in the different pathogenesis
of calcifications [9]. Haldimann et al. [10] studied the
effect of Practo-Clyss 120ml in two volunteers with
renal insufficiency. Similar to our patient, one of them
was a patient with non-functioning graft and bowel
motility 2 days after renal transplantation [10]. As with
our case, they saw an increase of serum phosphate with
a decrease of serum calcium, strongly suggesting
CaHPO4 precipitation. However, in our patient, the
incautious administration resulted in a catastrophe.
The hyperphosphataemia was accompanied by hypo-
tension and, given the pre-existing mesenteric athero-
and arteriolosclerosis, led to ischaemia in visceral
organs. Subsequently, phosphate overload and a high
serum calcium phosphate product caused severe
dystrophic calcifications. Especially, the sharp and
dramatic increase in liver enzymes and the liver infarcts
with calcifications may have been caused by hypoper-
fusion with subsequent dystrophic calcifications.
The same mechanism of hypoperfusion and ischaemia
may explain the extended calcifications in the pre-
damaged graft of a marginal donor.
This is, to our knowledge, the first published case
proven by autopsy, in which enema-induced hyper-
phosphataemia led to disseminated dystrophic calcifi-
cations in virtually all visceral organs. Despite two
haemodialysis sessions within 12 h to eliminate the
phosphate, the process of calcification could not be
reversed.
To know more about the use of phosphate-based
bowel preps in the post-operative period of kidney
transplantation, we performed a survey in 70 centres in
the Eurotransplant area and in Swisstransplant. The
response rate was 50% (35 centres). In 16 centres
(46%), phosphate-containing enemas are never used.
In 8 centres (23%), phosphate-containing preps are not
used in the immediate post-transplantation period.
Seven of them restrict the use of phosphate-containing
preps to a functioning graft, whereas the proposed
cut-off defining a functioning graft (expressed by
serum creatinine or creatinine clearance) varies widely
[serum creatinine less than 300mmol/l to 150mmol/l
(3.4–1.6mg/dl); creatinine clearance more than
20–40ml/min]. In 11 centres (31%), phosphate-based
enemas are prescribed in the post-operative period, of
which 10 centres (28%) use it without restriction for
functioning grafts and one centre limits its use to
normal serum phosphate levels. In summary, nearly
one-third of the centres which replied, use phosphate-
based preps without restriction to functioning graft.
The following conclusions can be drawn. First,
the potential seriousness of the adverse effects of
phosphate-based preps may still be underestimated,
especially in the early post-operative period in kidney
transplantation. Second, there exists no clear creatinine
cut-off which permits the safe application of
phosphate-based preps. It should be noted that in the
afore-mentioned study of Markowitz et al. [5] most of
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the patients had a baseline serum creatinine within the
normal range.
In conclusion, it is hazardous to administer
phosphate-based enemas in patients with renal insuffi-
ciency, especially in patients with a risk of increased
retention due to atonic bowel or faecal impaction.
In the early post-operative period of kidney transplan-
tation, the administration of phosphate-based enemas
is contraindicated.
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